Clinical trial
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the…
NCT00287742 · Janssen Pharmaceutical K.K., Industry · Terminated
Key facts
| NCT number | NCT00287742 |
|---|---|
| Title | A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease |
| Official title | Double-blind, Placebo-controlled Clinical Trial of JK6476 (Risperidone) in Patients With Hallucinations and Delusions Associated With Alzheimer's Disease |
| Lead sponsor | Janssen Pharmaceutical K.K., Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease, Dementia |
| Intervention type | Drug |
| Interventions | risperidone |
| Enrollment | 33 |
| Start date | Mar 1, 2002 |
| Completion | Mar 1, 2003 |
| First posted | Feb 7, 2006 |
| Last update posted | May 24, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: